New drug RSC-1255 takes on Hard-to-Treat cancers
NCT ID NCT04678648
First seen Jan 12, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This early-stage trial is testing an experimental drug called RSC-1255, taken alone or with hydroxychloroquine, in people with advanced solid tumors (such as lung, colon, or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then checking for early signs of effectiveness. About 134 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon, SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon, SCRI Oncology Partners - Health One
RECRUITINGDenver, Colorado, 80218, United States
-
University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology
RECRUITINGLos Angeles, California, 90404, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSC-1255 (an experimental drug taken orally, sometimes combined with hydroxychloroquine)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with a small number of participants, so the drug may not prove safe or effective. Side effects are unknown, and many early-stage drugs never advance to become treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.